Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELAVL1 | Q15717 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22130653 | 0.96 | ELAVL1 (0.58) | ELAVL1POLBKMT2AMEN1LMNA | |
| SCHEMBL22130633 | 0.81 | ELAVL1 (0.59) | ELAVL1KMT2AMEN1LMNAHPGD | |
| SCHEMBL22130727 | 0.78 | ELAVL1 (0.44) | ELAVL1KMT2AMEN1HPGDMAPT | |
| SCHEMBL22130699 | 0.78 | ELAVL1 (1.00) | ELAVL1KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL22130675 | 0.74 | ELAVL1 (0.92) | ELAVL1KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL22130676 | 0.72 | KDM4E (0.40) | ELAVL1POLBKMT2AMEN1LMNA | |
| SCHEMBL22130708 | 0.69 | KDM4E (0.39) | ELAVL1KMT2AMEN1LMNAHPGD | |
| SCHEMBL22130721 | 0.68 | ELAVL1 (0.40) | ELAVL1HPGDHTTALDH1A1 | |
| SCHEMBL22130735 | 0.68 | HPGD (0.41) | ELAVL1KMT2AMEN1LMNAHPGD | |
| SCHEMBL22130678 | 0.65 | MEN1 (0.39) | ELAVL1KMT2AMEN1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | UNIVERSITA' DEGLI STUDI DI TRENTO (IT) | 2020-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | AZI2, TPMT, TYMS | ELAVL1 2765/4885POLB 964/4885KMT2A 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.